1. HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent
Expiries, Increased Uptake of Once-a-Day Fixed-dose
Combination Drugs to Drive Growth
Report Details:
Published:November 2012
No. of Pages: 111
Price: Single User License – US$3500
HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of
Once-a-Day Fixed-dose Combination Drugs to Drive Growth
Summary
GBI Research, a leading business intelligence provider, has released its latest research,
“HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of
Once-a-Day Fixed-dose Combination Drugs to Drive Growth”. The report provides insights into the
Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome) HIV/AIDS therapeutics
market including market forecasts up to 2018. It provides an in-depth analysis of the major
marketed products, as well as insights into the HIV/AIDS therapeutics R&D pipeline. The report
provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV/AIDS
therapeutics market. The report analyzes the market for HIV/AIDS therapeutics in the US, the top
five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report
provides branded and generics segmentation in the therapeutic landscape segment. In addition, it
analyzes the HIV/AIDS therapeutics market in India, China and Australia. The report discusses the
global pipeline for all the HIV/AIDS molecules across various stages of development. The report is
built using data and information sourced from proprietary databases, primary and secondary
research and in-house analysis by GBI Research’s team of industry experts.
GBI Research found that the HIV/AIDS therapeutics market in the top seven markets was valued
at $13.5 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 12.5% during
the 2004–2011 historic period. The market is projected to witness growth of 7% during the
2011–2018 forecast period to reach $21.8 billion. The growth is primarily driven by the increase in
the use of single dose multi-class combination drugs such as Atripla, Complera. With the recent
launch of Stribild (previously known as Quad), the multi-class combination drugs would drive the
market.

2. Scope
- Annualized market data for the HIV/AIDS therapeutics market from 2004 to 2011, forecast
forward to 2018.
- Analysis of the HIV/AIDS therapeutics market in the leading geographies of the world, which
includes the US, the UK, Germany, France, Italy, Spain, and Japan.
- Analysis of the HIV/AIDS therapeutics market in India, China and Australia.
- Market characterization of the HIV/AIDS therapeutics market including market size, annual cost
of treatment, and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. Key companies studied in this report are
Gilead Sciences, Bristol-Myers Squibb, GlaxoSmithKline, Abbott Laboratories, Johnson &
Johnson, Merck, and Roche.
- Key M&A activities and licensing agreements that have taken place between 2008 and up to
June 2012 in the global HIV/AIDS therapeutics market.
Reasons to buy
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and
HIV/AIDS therapeutics market segments poised for strong growth.
- Create a more tailored country strategy through the understanding of key drivers and barriers of
the global HIV/AIDS therapeutics market.
- Develop key strategic initiatives by understanding the key focus areas and top selling products of
leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers,
acquisitions and strategic partnerships.
Get your copy of this report @
http://www.reportsnreports.com/reports/206064-hiv-aids-therapeutics-market-to-2018-despite-major-patent-
expiries-increased-uptake-of-once-a-day-fixed-dose-combination-drugs-to-drive-growth.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 9
2 HIV/AIDS Therapeutics Market to 2018 - Introduction 11
3 HIV/AIDS Therapeutics Market to 2018 - Overview 12
3.1 Disease Overview 12
3.1.1 Diagnostic Tests for HIV 13

3. 3.2 WHO Guidelines for HIV/AIDS Treatment 14
3.2.1 WHO Clinical Staging of HIV Disease in Adults and Adolescents 15
3.2.2 Summary of Changes to the WHO’s Guidelines on Initiation of ART based on CD4 Count
and Clinical Staging 16
3.2.3 Summary of Changes to WHO’s Guidelines on First-line Antiretrovirals 17
3.2.4 Summary of Changes to the WHO’s Guidelines on Second-line Antiretrovirals 18
3.3 Drugs Classes Used in HIV/AIDS Treatment 19
3.3.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors 19
3.3.2 Non-nucleoside Reverse Transcriptase Inhibitors 20
3.3.3 Protease Inhibitors 20
3.3.4 Fusion Inhibitors 21
3.3.5 CCR5 Co-receptor Antagonist 21
3.3.6 Integrase Inhibitors 21
3.3.7 Multi-class Combination Drugs 22
3.4 Key Marketed Products 23
3.4.1 Atripla 23
3.4.2 Truvada 25
3.4.3 Reyataz 27
3.4.4 Sustiva 28
3.4.5 Isentress 29
3.5 Advancements in HIV/AIDS Vaccine Research 30
4 HIV/AIDS Therapeutics Market to 2018 - Market Characterization and Forecast 31
4.1 Introduction 31
4.2 Revenue Forecast 32
4.2.1 Market Share by Drug Class (%), 2011 33
4.3 Branded Versus Generics Market Share (%), 2011 34
4.4 Market Share by Company (%), 2011 35
4.5 Annual Cost of Therapy 36
4.6 Treatment Usage Pattern 38
4.6.1 Diseased Population 39
4.6.2 Diagnosed Population 39
4.6.3 Prescription Population 39
4.7 HIV/AIDS Therapeutics Market - Drivers and Restraints 40
4.7.1 HIV/AIDS Therapeutics Market - Drivers 40
4.7.2 Market Restraints 42
5 HIV/AIDS Therapeutics Market to 2018 - The US 45
5.1 Market Overview 45
5.2 Revenue Forecast 45
5.3 Annual Cost of Therapy 46
5.4 Treatment Usage Pattern 47
5.4.1 Diseased Population 48
5.4.2 Diagnosed Population 48

4. 5.4.3 Prescription Population 48
6 HIV/AIDS Therapeutics Market to 2018 - Top Five European Countries 49
6.1 Market Overview 49
6.2 Revenue Forecast: Top Five European Countries 49
6.3 Revenue by Geographical Segmentation 50
6.4 Annual Cost of Therapy 51
6.5 Treatment Usage Pattern 52
6.5.1 Diseased Population 53
6.5.2 Diagnosed Population 53
6.5.3 Prescription Population 53
7 HIV/AIDS Therapeutics Market to 2018 - Japan 54
7.1 Market Overview 54
7.2 Revenue Forecast 54
7.3 Annual Cost of Therapy 55
7.4 Treatment Usage Pattern 56
7.4.1 Diseased Population 57
7.4.2 Diagnosed Population 57
7.4.3 Prescription Population 57
8 HIV/AIDS Therapeutics Market to 2018 - Emerging Markets 58
8.1 China 58
8.1.1 Epidemiology 58
8.1.2 Important Events in China’s HIV/AIDS Policy Development 59
8.1.3 Clinical Trials in China 60
8.2 India 61
8.2.1 Overview 61
8.2.2 National AIDS Control Programs 63
8.2.3 Treatment Guidelines 64
8.2.4 Trade Related Aspects of Intellectual Property Rights Agreement and its Impact on Generics
65
8.2.5 Recent Developments in HIV/AIDS Therapeutics Market in India 65
8.3 Australia 66
8.3.1 Overview 66
8.3.2 Highly Specialized Drugs (Section 100) Program 67
9 HIV/AIDS Therapeutics Market to 2018 - Pipeline Analysis 70
9.1 Overview 70
9.2 Promising Molecules in Late Stages of Clinical Development 71
9.2.1 Stribild (Quad) 71
9.2.2 Cobicistat 73
9.2.3 JTK-303 74
9.2.4 1349572 75
9.2.5 572-Trii 76
10 HIV/AIDS Therapeutics Market to 2018 - Competitive Landscape 78

5. 10.1 Introduction 78
10.2 Major Company Profiles 79
10.2.1 Gilead Sciences, Inc 79
10.2.2 GlaxoSmithKline (GSK) 80
10.2.3 BMS 82
10.2.4 Abbott Laboratories 83
10.2.5 Merck 84
10.2.6 Johnson & Johnson (J&J) 85
10.2.7 Roche 86
11 HIV/AIDS Therapeutics Market to 2018 - Strategic Consolidations 87
11.1 Deals by Year 87
11.2 Deals by Type 88
11.2.1 Deals by Value 97
11.3 Deals by Geography 98
11.4 Summary of Major M&A Deals 99
11.4.1 Daiichi Sankyo Acquires Majority Stake in Ranbaxy Labs 99
11.4.2 Endo Pharma Acquires Indevus Pharma 99
11.5 Summary of Major Licensing Deals 99
11.5.1 GlaxoSmithKline Enters into Licensing Agreement with Idenix Pharma 99
11.5.2 BMS Enters into Licensing Agreement with Oncolys BioPharma 99
11.6 Summary of Major Partnerships 100
11.6.1 GlaxoSmithKline Enters into an Agreement with Concert Pharma 100
11.6.2 Chemrar Enters into Joint Venture Agreement with Rusnano 100
11.6.3 GenVec Enters into an Agreement with SAIC-Frederick 100
12 HIV/AIDS Therapeutics Market to 2018 - Appendix 101
12.1 Market Definitions 101
12.2 Abbreviations 101
12.3 Bibliography 103
12.4 Research Methodology 105
12.4.1 Coverage 105
12.4.2 Secondary Research 106
12.4.3 Primary Research 106
12.5 Therapeutic Landscape 107
12.5.1 Epidemiology-based Forecasting 107
12.5.2 Market Size by Geography 109
12.6 Geographical Landscape 109
12.7 Pipeline Analysis 110
12.8 Competitive Landscape 110
12.8.1 Expert Panel Validation 110
12.9 Contact Us 110
12.10 Disclaimer 111

6. 1.1 List of Tables
Table 1: HIV/AIDS Therapeutics Market to 2018, WHO Clinical Staging of HIV Disease in Adults
and Adolescents, 2010 15
Table 2: HIV/AIDS Therapeutics Market to 2018, Summary of Changes to the WHO’s Guidelines
on Initiation of Antiretroviral Therapy Based on CD4 Count and Clinical Staging, 2010 16
Table 3: HIV/AIDS Therapeutics Market to 2018, Summary of Changes to WHO’s Guidelines on
First-line Antiretrovirals, 2010 17
Table 4: HIV/AIDS Therapeutics Market to 2018, Summary of Changes to WHO’s Guidelines on
Second-line Antiretrovirals, 2010 18
Table 5: HIV/AIDS Therapeutics Market to 2018, Nucleoside/Nucleotide Reverse Transcriptase
Inhibitors, Global Sales ($m), 2011 19
Table 6: HIV/AIDS Therapeutics Market to 2018, Non-Nucleoside Reverse Transcriptase
Inhibitors, Global Sales ($m), 2011 20
Table 7: HIV/AIDS Therapeutics Market to 2018, Protease Inhibitors, Global Sales ($m), 2011 20
Table 8: HIV/AIDS Therapeutics Market to 2018, Fusion Inhibitors, Global Sales ($m), 2011 21
Table 9: HIV/AIDS Therapeutics Market to 2018, CCR5 Co-receptor Antagonist Global Sales ($m),
2011 21
Table 10: HIV/AIDS Therapeutics Market to 2018, Integrase Inhibitors Global Sales ($m), 2011 21
Table 11: HIV/AIDS Therapeutics Market to 2018, Multi-class Combination Drugs, Global Sales
($m), 2011 22
Table 12: HIV/AIDS Therapeutics Market to 2018, Global, Market Share of Key Products (%),
2011 23
Table 13: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue ($bn), 2004-2011
32
Table 14: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue Forecast ($bn),
2011-2018 32
Table 15: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy
($), 2004-2011 36
Table 16: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy
Forecast ($), 2011-2018 36
Table 17: HIV/AIDS Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000),
2004-2011 38
Table 18: HIV/AIDS Therapeutics Market, Top Seven Markets, Treatment Usage Pattern Forecast
(‘000), 2011-2018 38
Table 19: HIV/AIDS Therapeutics Market to 2018, The US, Patent Expiries, 2012-2018 44
Table 20: HIV/AIDS Therapeutics Market to 2018, The US, Revenue ($bn), 2004-2011 45
Table 21: HIV/AIDS Therapeutics Market to 2018, The US, Revenue Forecast ($bn), 2011-2018
45
Table 22: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy ($), 2004-2011
46
Table 23: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy Forecast ($),
2011-2018 46

7. Table 24: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern (‘000), 2004-
2011 47
Table 25: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern Forecast
(‘000), 2011-2018 47
Table 26: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue ($bn),
2004-2011 49
Table 27: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue
Forecast ($bn), 2011-2018 49
Table 28: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue by
Geographical Segmentation ($m), 2004-2011 50
Table 29: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue
Forecast by Geographical Segmentation ($m), 2011-2018 50
Table 30: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of
Therapy ($), 2004-2011 51
Table 31: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of
Therapy Forecast ($), 2011-2018 51
Table 32: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment
Usage Pattern (‘000), 2004-2011 52
Table 33: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment
Usage Pattern Forecast (‘000), 2011-2018 52
Table 34: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue ($m), 2004-2011 54
Table 35: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue Forecast ($m), 2011-2018 54
Table 36: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy ($), 2004-2011
55
Table 37: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy Forecast ($),
2011-2018 55
Table 38: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern (‘000), 2004-
2011 56
Table 39: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern Forecast
(‘000), 2011-2018 56
Table 40:HIV/AIDS Therapeutics Market, China, Diseased Population (‘000), 2005-2011 58
Table 41: HIV/AIDS Therapeutics Market, Pipeline Molecules, China, 2012 60
Table 42: HIV/AIDS Therapeutics Market to 2018, India, ART Centre Coverage and Patients on
First-line Therapy, 2005-2010 62
Table 43: HIV/AIDS Therapeutics Market to 2018, India, HIV/AIDS Prevalence, 2004-2009 62
Table 44: HIV/AIDS Therapeutics Market to 2018, India, Treatment Guidelines, 2011 64
Table 45: HIV/AIDS Therapeutics Market to 2018, Australia, Number of HIV Cases and MSM (%),
2001-2010 66
Table 46: HIV/AIDS Therapeutics Market to 2018, Australia, List of Approved Medications Under
Highly Specialized Drugs (Section 100) Program, 2012 68
Table 47: HIV/AIDS Therapeutics Market to 2018, Australia, Number of People Prescribed ART
through the Highly Specialized Drugs (S100) Program, 2006-2010 69

8. Table 48: HIV Therapeutics Market, Global, Number of Molecules in Pipeline by Phase, 2012 70
Table 49: HIV Therapeutics Market, Global, Promising Molecules in Late Stages of Clinical
Development, 2012 71
Table 50: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by
Type, 2008-2012 88
Table 51: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Mergers and
Acquisitions Deals, 2008-2012 89
Table 52: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Partnership
Deals, 2008-2012 90
Table 53: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Partnership
Deals, 2008-2012 92
Table 54: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing
Deals, 2008-2012 93
Table 55: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing
Deals, 2008-2012 94
Table 56: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing
Deals, 2008-2012 95
Table 57: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by
Value ($m), 2008-2012 97
Table 58: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by
Geography, 2008-2012 98
1.2 List of Figures
Figure 1: HIV/AIDS Therapeutics Market to 2018, Global, Treatment Algorithm, 2012 13
Figure 2: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Revenue Forecast ($bn),
2004-2018 32
Figure 3: HIV/AIDS Therapeutics Market to 2018, Global, Market Share by Drug Class (%), 2011
33
Figure 4: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Branded Versus Generics
Market Share (%), 2011 34
Figure 5: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Market Share by Company
(%), 2011 35
Figure 6: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Annual Cost of Therapy ($),
2004-2018 36
Figure 7: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Treatment Usage Pattern
(‘000), 2004-2018 38
Figure 8: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Drivers and Restraints,
2012 40
Figure 9: HIV/AIDS Therapeutics Market to 2018, The US, Revenue Forecast ($bn), 2004-2018 45
Figure 10: HIV/AIDS Therapeutics Market to 2018, The US, Annual Cost of Therapy ($), 2004-
2018 46
Figure 11: HIV/AIDS Therapeutics Market to 2018, The US, Treatment Usage Pattern (‘000),

9. 2004-2018 47
Figure 12: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue
Forecast ($bn), 2004-2018 49
Figure 13: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Revenue
Forecast by Geographical Segmentation ($m), 2004-2018 50
Figure 14: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Annual Cost of
Therapy Forecast ($), 2004-2018 51
Figure 15: HIV/AIDS Therapeutics Market to 2018, Top Five European Countries, Treatment
Usage Pattern (‘000), 2004-2018 52
Figure 16: HIV/AIDS Therapeutics Market to 2018, Japan, Revenue Forecast ($m), 2004-2018 54
Figure 17: HIV/AIDS Therapeutics Market to 2018, Japan, Annual Cost of Therapy ($), 2004-2018
55
Figure 18: HIV/AIDS Therapeutics Market to 2018, Japan, Treatment Usage Pattern (‘000), 2004-
2018 56
Figure 19: HIV/AIDS Therapeutics Market, China, Diseased Population (‘000), 2005-2011 58
Figure 20: HIV/AIDS Therapeutics Market, Important Events in China’s HIV/AIDS Policy
Development, 1985-2012 59
Figure 21: HIV/AIDS Therapeutics Market to 2018, India, ART Centre Coverage and Patients on
First Line Therapy, 2005-2010 61
Figure 22: HIV/AIDS Therapeutics Market to 2018, India, HIV/AIDS Prevalence, 2004-2009 62
Figure 23: HIV/AIDS Therapeutics Market to 2018, Australia, Number of Diagnosed HIV Cases
and MSM (%), 2001-2010 66
Figure 24: HIV/AIDS Therapeutics Market to 2018, Global, Pipeline by Phase (%), 2012 70
Figure 25: HIV/AIDS Therapeutics Market to 2018, Top Seven Markets, Market Share by
Company (%), 2011 78
Figure 26: HIV/AIDS Therapeutics Market to 2018, Gilead Sciences, SWOT Analysis, 2012 79
Figure 27: HIV/AIDS Therapeutics Market to 2018, GSK, SWOT Analysis, 2012 81
Figure 28: HIV/AIDS Therapeutics Market to 2018, BMS, SWOT Analysis, 2012 82
Figure 29: HIV/AIDS Therapeutics Market to 2018, Abbott, SWOT Analysis, 2012 83
Figure 30: HIV/AIDS Therapeutics Market to 2018, Merck, SWOT Analysis, 2012 84
Figure 31: HIV/AIDS Therapeutics Market to 2018, J&J, SWOT Analysis, 2012 85
Figure 32: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by
Year, 2008-2012 87
Figure 33: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by
Type (%), 2008-2012 88
Figure 34: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by
Value (%), 2008-2012 97
Figure 35: HIV/AIDS Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by
Geography (%), 2008-2012 98
Figure 36: GBI Research Market Forecasting Model 109
Contact: sales@reportsandreports.com for more information.